Anavex Life Sciences is a clinical stage biopharmaceutical company engaged in the development of therapeutics by applying medicine to central nervous system diseases. Co.'s proprietary SIGMACEPTOR™ Discovery Platform produced small molecule drug candidates with certain modes of action, based on its understanding of sigma receptors. Sigma receptors may be targets for therapeutics to combat many human diseases, both of neurodegenerative nature, including Alzheimer's disease, as well as of neurodevelopmental nature, like Rett syndrome. Compounds that have been subjects of Co.'s research include the following: ANAVEX®2-73 (blarcamesine), ANAVEX®3-71, ANAVEX®1-41, and ANAVEX®1066, ANAVEX®1037. We show 37 historical shares outstanding datapoints in our AVXL shares outstanding history coverage, used to compute AVXL market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing AVXL market cap history over the course of time is important for investors
interested in comparing AVXL's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of AVXL versus a peer is one thing; comparing
AVXL market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like AVXL can fluctuate over the course of history.
With this page we aim to empower investors researching AVXL by allowing them to research the AVXL market cap history. |
Free AVXL Email Alerts:
Video: The Importance of Market Cap
